Save Product
Product Details
Source
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) is a chimeric monoclonal antibody recombinantly expressed from HEK293 cells, which combines the variable region of a mouse monoclonal antibody with human IgG1 constant domain. The mouse monoclonal antibody was obtained from a mouse immunized with recombinant SARS-CoV-2 Spike S1 protein. As verified in competitive ELISA-based and pseudovirus-based neutralization assay, this chimeric monoclonal can potently neutralize all SARS-CoV-2 Variants of Concern (VOCs), including Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529).
Clone
AM122
Isotype
Human IgG1 | Human Kappa
Conjugate
Unconjugated
Antibody Type
Recombinant Monoclonal
Reactivity
Virus
Specificity
This product is a specific antibody against SARS-CoV-2 Spike protein RBD domain. No cross-reactivity is detected with Spike protein RBD domain of other coronaviruses, including SARS-CoV, MERS-CoV, HCoV-229E, HCoV-NL63, HCoV-OC43 and HCoV-HKU1.
Application
ApplicationRecommended UsageELISA0.2-50 ng/mLPurity
95% as determined by SDS-PAGE.
Purification
Protein A purified / Protein G purified
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Bioactivity-ELISA
Immobilized SARS-CoV-2 S1 protein, His Tag (Cat. No. S1N-C52H2) at 2 μg/mL (100 μL/well) can bind Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) (Cat. No. S1N-M122) with a linear range of 0.2-3 ng/mL (QC tested).
Protocol
Detection of SARS-CoV-2 S protein RBD by Sandwich ELISA Assay.
Immobilized Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) (Cat. No. S1N-M122) at 2 μg/mL (100 μL/well) can bind Spike RBD (Cat. No. SPD-C52H1). And then add Biotinylated Anti-SARS-CoV-2 Spike RBD Antibody, Chimeric mAb, Human IgG1 (AM130) (Cat. No.S1N-M13L3) at 0.2 μg/mL. Detection was performed using HRP-conjugated streptavidin with sensitivity of 0.05 ng/mL (Routinely tested).Protocol
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) (Cat.No. S1N-M122) neutralizes SARS-CoV-2 Spike RBD by inhibiting RBD: ACE2 interaction. The ACE2-coated plate is incubated with the wild type (WT) RBD or B.1.1.7, B.1.351, P.1, B.1.617.1, B.1.617.2 mutant and treated with the neutralizing antibody at increasing concentration. Percent inhibition is calculated based on the OD value.
Protocol
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) (Cat.No. S1N-M122) neutralizes SARS-CoV-2 (Omicron) Spike Trimer (Cat. No. SPN-C52Hz) by inhibiting Spike: ACE2 interaction. The ACE2-coated plate was incubated with the SARS-CoV-2 (Omicron) Spike Trimer protein and treated with neutralizing antibody at increasing concentration. Percent inhibition was calculated based on the OD value.
Protocol
Bioactivity-SPR
Anti-SARS-CoV-2 Spike RBD Neutralizing Antibody, Chimeric mAb, Human IgG1 (AM122) (Cat. No. S1N-M122) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind SARS-CoV-2 S protein RBD, His Tag (Cat. No. SPD-C52H3) with an affinity constant of 0.375 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
Drug Candidate Licensing